Checkpoint Systems deploys its EAS Solutions at ... » Checkpoint Systems has announced its partnership in implementing EAS pedestals and deactivation syst... Evander Direct wins commendation for uPVC window... » Evander Direct have been commended for their innovative uPVC cleaning process that dramatically help... Electrical Industries Charity to benefit from pr... » Thousands of pounds are set to be raised for good causes in the electrotechnical industry at the upc... Secure I.T. Environments achieves new internatio... » Data Centre World, London: Secure I.T. Environments Ltd has announced that it has achieved new inter... OKI upgrades wide format with new Teriostar Multif... » Egham: OKI Europe Ltd has launched two new wide format Teriostar multifunction printers designed to ... BSIA members push aggressively for cyber-security ... » BSIA members have pledged to lead the way in cyber-security education, Vigilance can report. Smart access integration mitigates risk » ASDA SHOP FLOOR Cortech Developments’ main software product, Datalog 5, now offers full integration... Businesses warned to be extra vigilant with person... » BSIA Information Destruction section has warned businesses to be extra vigilant with personal data a... Osirium accelerates global channel recruitment pla... » · Distributor appointed in Middle East and North Africa (MENA) Reading, UK: Osirium Technologies pl... Misys recognised as leader in FRTB » London, UK: Misys has been recognised as a leader in helping banks meet the requirements of the Fund...

CLICK HERE TO

Health Security Header

LONDON, UK: The UK Department of Health’s rejection of an 800,000-signature public petition to expand the routine administration of the only approved vaccine to offer protection against invasive meningococcal disease (IMD) caused by serogroup B (MenB), may lead to parents and physicians to consider purchasing the vaccine themselves, according to an analyst with research and consulting firm GlobalData.

The decision to keep free access to GlaxoSmithKline’s MenB vaccine, Bexsero, limited to infants rather than vaccinating children up to 11 years of age, as requested in the petition, is a significant setback for the advocacy groups and parents aiming for expanded vaccine administration.

Mirco Junker, Ph.D., GlobalData’s Analyst covering Infectious Diseases, explains: “Even though IMD cases caused by serogroups B and C are most prevalent, the majority of European countries only routinely administer meningococcal vaccines against serogroup C, which provide excellent safety and efficacy profiles in combination with relatively low price points. MenB vaccines, on the other hand, are relatively new and expensive, and there is only limited clinical data demonstrating their long-term effectiveness.

“This uncertainty regarding the long-term efficacy - together with studies indicating low cost-effectiveness of MenB vaccines - also highlights the general conflicts rare diseases like IMD bring up when medical needs are pitted against the commercial viability of vaccines. Indeed, vaccinating entire populations against rare diseases can be extremely challenging to rationalize from a pharmacoeconomic perspective.”

In fact, in 2014, a study using the analysis of quality-adjusted life-years indicated that the new MenB vaccine would not be cost-effective even if provided to the National Health Service (NHS) for less than £1 per dose. However, cost-effectiveness should not be viewed as the main determining factor for the broad application of a vaccine against a rare disease, as many vaccines might not pass this threshold, given low enough disease prevalence.

Junker continues: “While the Department of Health’s decision is a disappointment for parents worried about their children developing IMD, GlobalData believes it is understandable from the perspective of the NHS, as healthcare costs continue to rise and governmental agencies have to balance the restraints of a limited budget with society’s medical needs.

“A reasonable compromise could be to provide individual families concerned about IMD to purchase vaccines out-of-pocket without having to face the list price of the vaccine. As such, it might be in the interest of the pharmaceutical industry to provide incentives to make the vaccine available to individuals not covered under the NHS guidelines.”